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Can Intestinal Fatty Acid Binding Protein (I-FABP) 
Be A Marker in the Diagnosis of Abdominal Pathology?
FABP’nin İntestinal Tipi (I-FABP) Abdominal Patolojilerin Tanısında Belirteç Olabilir mi?
SUMMARY
Objectives
Biochemical markers play an important role in the early diagnosis 
of abdominal pain. This study aimed to investigate the diagnostic 
value of intestinal type fatty acid binding protein (I-FABP) in pa-
tients with abdominal pathology.
Methods
This prospective and descriptive study was performed at the Uni-
versity Hospital Emergency Department. Serum I-FABP levels of 
patients presenting with acute abdominal pain were measured at 
time of admission and were compared with those of healthy indi-
viduals.
Results
The mean I-FABP level of the 171 patients enrolled in this study 
was 170.1±543.4 pg/ml, while that of a healthy control group was 
61.4±47.4 pg/ml. Although I-FABP levels were higher in the patient 
group, this difference was not statistically significant (p>0.05). 
However, I-FABP levels of patients with mesenteric ischemia and in-
tra-abdominal mass were significantly higher than those of healthy 
individuals (p<0.05).
Conclusions
I-FABP levels that are evaluated at time of admission in patients 
presenting with abdominal pain to the emergency department are 
significantly higher in patients with mesenteric ischemia and intra-
abdominal mass than are those of healthy individuals.
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ÖZET
Amaç
Biyokimyasal belirteçler karın ağrısının sebebinin erken tanısında ol-
dukça önemlidir. Bu çalışmada FABP’nin intestinal tipinin (I-FABP) ab-
dominal patolojisi olan hastaların ayırıcı tanısındaki değeri araştırıldı.
Gereç ve Yöntem
Mevcut çalışma üniversite hastanesi acil servisinde ileriye yönelik ta-
nımlayıcı olarak çalışma gerçekleştirildi. Karın ağrısı şikayeti ile acil ser-
vise başvuran hastalarda başvuru anında alınan serum örneklerinden 
I-FABP değerlerine bakıldı. Bulgular sağlıklı gönüllülerdeki düzeyler ile 
karşılaştırıldı.
Bulgular
Kayıtlı 171 hastada ölçülen ortalama I-FABP seviyesi 170.1±543.4 pg/
ml olarak belirlendi. Sağlıklı gönüllülerde I-FABP seviyesi 61.4±47.4 pg/
ml olarak bulundu. Hasta grubunun I-FABP seviyeleri sağlıklı gönüllü-
lere göre yüksek olarak bulunmuşsa da, aradaki fark istatistiksel ola-
rak anlamlı değildi (p>0.05). Başvuru anında ölçülen I-FABP seviyeleri 
sağlıklı gönüllülerle kıyaslandığında akut mezenter iskemide (AMI) ve 
karıniçi kitle tespit edilen hastalarda istatistiksel olarak anlamlı yük-
sekti (p<0.05).
Sonuç
Acil servise karın ağrısı şikayeti ile başvuran hastalardan mezenter 
iskemi ve karıniçi kitle tanısı alan hastalarda başvuru anında ölçülen 
serum I-FABP değerleri sağlıklı gönüllülere kıyaslandığında anlamlı 
olarak yüksek bulunmuştur.
Anahtar sözcükler: Karın ağrısı; batında kitle; I-FABP; mezenter iskemisi.
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Introduction
Biochemical markers can be easily obtained, are widely used, 
and are becoming very important in the early diagnosis of 
abdominal pathology. Specific biochemical markers have 
been reported for several pathologies, including alanine 
aminotransferase for hepatic injury and amylase for pan-
creatitis.[1] Although several studies have been published 
regarding this issue, several abdominal pathologies have no 
specific biochemical markers. These previously published 
studies include investigations regarding the diagnostic and 
prognostic values of D-dimer, MMP-9, IMA, I-FABP, alpha glu-
tathione S transferase, D-lactate and S100 A8/A9 levels in 
patients with abdominal pain.[2-8]
Fatty acid binding protein (FABP) is a small (12-15 kDa) 
intracellular protein that increases in conditions such as 
inflammation and ischemia. It plays a role in protecting 
cells from the side effects of fatty acids and increases in 
association with various pharmacological and pathophysi-
ological effects, such as ischemia.[9] Several types of FABP 
have been described immunologically, including heart, 
intestinal, liver, epidermal, muscle and adipocyte. Intesti-
nal FABP (I-FABP) is located exclusively in gastric epithe-
lial cells and intestinal mucosa.[10] Recently, Vermeulen et 
al. reported that I-FABP levels increase significantly due to 
intestinal ischemia after aortic surgery.[11] Another study 
by Relja et al. showed that I-FABP and liver FABP (L-FABP) 
levels increase after abdominal trauma and are correlated 
with the severity of abdominal tissue injury in patients 
with polytrauma.[12]
The purpose of this study was to compare I-FABP levels in 
patients admitted to the emergency department with ab-
dominal pain and who were preliminarily diagnosed with 
abdominal pathology with I-FABP levels in a healthy control 
group. This study was based on the hypothesis that I-FABP 
may be a useful diagnostic marker in the differential diagno-
sis of abdominal pathology.
Materials and Methods 
This prospective and descriptive study was performed with 
patients who presented to our University Hospital Emer-
gency Department between June 2009 and June 2010 
with abdominal pain and who were diagnosed with ab-
dominal pathology by emergency physicians and general 
surgeons. Patients were diagnosed on the basis of physical 
examination, ultrasonography and computerized tomogra-
phy. Patients with trauma (n=80), pain lasting longer than 
48 hours (n=24), those who were younger than 18 years 
(n=46), those who were unavailable for monitoring (n=13) 
and those who declined to participate (n=23) were exclud-
ed from the study. The control group consisted of age and 
gender matched healthy hospital employees with no his-
tory of abdominal pathology. Approval for this study was 
obtained from the Ethics Committee of Karadeniz Technical 
University, Turkey (2009-21). Patients enrolled in the study 
were registered using a form that included demographic 
data, written permission, and routine patient evaluation 
data such as histories, physical examination results, bio-
chemical values and radiological results. Venous blood 
specimens (10 cc) were taken from patients who presented 
to the emergency department with abdominal pain in or-
der to measure serum I-FABP levels. Serum specimens ob-
tained by centrifugation at 3000 x g for 10 min were kept 
at -20ºC for a maximum of 6 months. Serum I-FABP levels 
were measured simultaneously at the end of the collection 
process.
Human serum I-FABP levels from patients and healthy indi-
viduals were measured using a commercial ELISA (Enzyme-
Linked Immunosorbent Assay kit; Hycult Biotech, the Neth-
erlands) kit according to the manufacturer’s instructions. 
Absorbance values were measured using a VERSA max 
tunable microplate reader (designed by Molecular Devices 
in California, USA) at a wavelength of 450 nm. Results were 
expressed as picograms/mL.
Data were analyzed using SPSS version 10.0. Standard devia-
tions of means and percentage frequency distributions were 
used as descriptive statistics. Normal distributions were cal-
culated using the Kolmogorov-Smirnov test for numeric 
data. Nonparametric data were analyzed using the Mann-
Whitney U test. The chi-square test was used for analyzing 
nominal parameters.
The sensitivity, specificity, positive predictive value (PPV), 
negative predictive value (NPV) and optimal cut-off value of 
I-FABP in patients presenting with abdominal pain were cal-
culated using a receiver operating curve (ROC) analysis. The 
ROC analysis was used to determine the causes of abdomi-
nal pain for which the mean I-FABP levels were higher than 
those in healthy individuals.
Results
Three hundred and one cases were enrolled in this study, 
with 130 in the control group and 171 in the patient group. 
The mean age of the patient group was 52±21 years (range: 
18-92 years) and was 56±8 years for healthy individuals.
The mean I-FABP level in the 171 patients was 170.1±543.4 
pg/ml and was 61.4±47.4 pg/ml in the 130 healthy volun-
teers. Although the I-FABP levels in the patient group were 
higher than those in the healthy individuals, this difference 
was not statistically significant (p>0.05).
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The patients were definitively diagnosed as follows: 11 
(6.4%) with appendicitis, 30 (17.5%) with gall bladder dis-
eases, 17 (9.9%) with ileus-volvulus, 14 (8.2%) with pan-
creatitis, 7 (4.1%) with mesenteric ischemia, 6 (3.5%) with 
ovarian diseases, 15 (8.8%) with intra-abdominal mass, 2 
(1.2%) with gastritis-peptic ulcer, 11 (6.4%) with nephroli-
thiasis-urolithiasis, 4 (2.3%) with herniation, 1 (0.6%) with 
perforation and 51 (29.8%) with non-specific abdominal 
pain.
The patients’ I-FABP levels were expressed as groups and 
subgroups (Table 1). The average values for the acute mes-
enteric ischemia group and the intra-abdominal mass group 
were 708.6±669.1 pg/ml and 387.4±1380.2 pg/ml, respec-
tively.
Our results show that the mesenteric ischemia and intra-ab-
dominal mass patients were the only patients whose I-FABP 
levels were significantly higher than those of the healthy 
individuals. In addition, the I-FABP levels of the mesenteric 
ischemia patients were significantly higher than those of the 
mass patients. I-FABP sensitivity, specificity and ROC curves 
for NPV and PPV values were determined for these 2 diseas-
es, and these data are shown in Figures 1 and 2.
The optimum cut-off I-FABP levels for the mesenteric isch-
emia and intra-abdominal mass patients according to ROC 
analysis as well as the sensitivity, specificity, NPV and PPV 
values for these levels are shown in Table 2.
The mean I-FABP level of the 49 patients who underwent 
surgery was 173.54387 pg/ml, and that of the 122 patients 
who did not undergo surgery was 168.6516 pg/ml. The dif-
ference between these values was not statistically signifi-
cant (p>0.05).
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Table 1. I-FABP values of patients admitted to the 
emergency department with abdominal pain 
at the time of presentation
Definitive Diagnosis (n) I-FABP levels pg/ml
 (Mean±SD)
Nonspecific abdominal pain (n=51) 53.5±55.7
Appendicitis (n=11) 73.9±131.4
Gall bladder diseases (n=30) 290.8±708.5
Ileus-volvulus (n=17) 130.8±221.9
Pancreatitis (n=14)  112.1±167.1
Mesenteric ischemia (n=7) 708.6±669.1*
Ovarian diseases (n=6) 129.3±261.2
Mass (n=15) 387.4±1380.2*
Gastritis–peptic ulcer (n=2) 65.1±34.1
Urolithiasis nephrolithiasis (n=11) 40.7±32.1
Hernia (n=4) 76.6±97.3
Perforation (n=1) 438.1
Total Patient (n=171) 170.1±543.3
Control (n=130) 61.4±47.4
*p<0.05 for mean I-FABP levels between the patient and control 
groups.
Figure 1.  ROC curve of I-FABP values showing cut-off value, sensi-
tivity, and specificity for mesenteric ischemia patients.
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Figure 2.  ROC curve of I-FABP values showing cut-off value, sensi-
tivity, and specificity for mass patients.
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Discussion
Abdominal pain can be simple, but it may also be associated 
with life-threatening pathology. The early diagnosis of acute 
abdominal pain in the emergency department is highly 
important, especially for pathologies that may require sur-
gical intervention. The most common etiological causes of 
abdominal pain are appendicitis, cholecystitis, small bowel 
obstruction, urinary colic, peptic ulcer perforation, pancre-
atitis and diverticulitis.[13] In their review of abdominal pain, 
Grundmann et al.[14] reported that the most frequent cause 
of acute abdominal pain was nonspecific abdominal pathol-
ogy (24%-44.3%), followed by appendicitis (15.9%-28.1%) 
and biliary disease (2.9%-9.7%). Similarly, the most common 
cause of acute abdominal pain in our study was nonspecific 
abdominal pathology (29.8%), followed by gall bladder dis-
eases (17.5%), ileus-volvulus (9.9%), intra-abdominal mass 
(8.8%), acute pancreatitis (8.2%), acute appendicitis (6.4%) 
and mesenteric ischemia (4.1%). The breakdown of patient 
groups in our study may be different from those previously 
published because our study was performed in a tertiary 
teaching and research hospital that works in co-ordination 
with other institutions.
Both clinical findings and laboratory tests are often used for 
diagnosing acute abdomen. White blood cell (WBC) count is 
an important and oft-used laboratory parameter,[15] and D-
dimer is frequently used in the evaluation of patients with 
acute abdominal pain.[1,16] Studies have reported that MMP-9 
levels are increased in patients with ureteral stones, acute 
cholecystitis and intestinal obstructions.[4] Significantly el-
evated ischemia modified albumin (IMA) levels have also 
been reported in mesenteric ischemia models.[5] Several re-
cent reviews have indicated that the most optimistic plasma 
biomarkers are I-FABP, alpha-glutathione S-transferase and 
D-lactate. I-FABP and alpha-glutathione S-transferase are lo-
calized in the mucosa of the small intestine. Since intestinal 
injury during acute mesenteric ischemia begins at the intes-
tinal mucosa, these markers can potentially be used in the 
early phase.[17] In addition, I-FABP, alpha-glutathione S-trans-
ferase and CK-MB levels differed significantly from the con-
trol group in a suspected acute mesentery ischemia popu-
lation. Serum phosphate level has also been investigated 
for the diagnosis of acute mesentery ischemia. Clinical and 
experimental studies have shown that the increase in serum 
phosphate levels in acute mesentery ischemia develops fol-
lowing ischemia-related intestinal necrosis and widespread 
cell death. Therefore, elevated serum phosphate is not a 
suitable marker for the early diagnosis of acute mesentery 
ischemia. However, it can be used as a prognostic indicator 
as well as an indicator of irreversible intestinal necrosis.[18,19]
Evennett et al.[1] reported that the most reliable plasma 
markers for intestinal ischemia are I-FABP, which is present 
in the mucosa of the small intestine, alpha-glutathione S-
transferase, and D-lactate, which is released from bacteria in 
the intestinal lumen as a product of bacterial fermentation. 
Another study showed that an alpha-glutathione S-transfer-
ase level <4 ng/ml has a 100% negative predictive value in 
eliminating ischemic intestinal disease. The same study also 
showed that the increase in alpha GST levels had a negative 
predictive value of 92% in patients with suspected acute 
mesentery ischemia.[6] Bealer et al.[7] determined a diagnos-
tic value of S100A8/A9 (calgranulin A/B) with 93% sensitivity 
and 54% specificity in patients with suspected acute appen-
dicitis.
In a clinical study investigating the use of I-FABP as a marker 
in acute abdomen cases, Kanda et al.[20-22] enrolled a total of 
96 individuals. Of these, 13 were diagnosed pre-surgically 
with ischemic intestinal disease (5 cases of mesenteric 
ischemia and 8 of strangulated hernia), 48 had a diagnosis 
of acute abdomen, and 35 served as healthy controls. This 
study also reported significantly high I-FABP values (>100 
ng/mL) in 5 cases with mesenteric ischemia.
Tölle et al.[23] reported elevated B-FABP in renal cell carcino-
ma patients and recommended that wider series be inves-
tigated to determine whether B-FABP could act as a tumor 
marker. Abdominal mass may cause ischemia, inflammation 
and intestinal membrane cell destruction, which do not typ-
ically lead to elevated FABP. These secondary causes may be 
assistant factors in these proteins being released into serum.
In our study with 171 patients and 130 healthy controls, the 
mean I-FABP levels were 170 pg/ml in the patient group and 
61 pg/ml in the control group. Although there was a consid-
erable numerical difference between these two means, this 
difference was not significant. Among the abdominal pa-
thologies included in our study, I-FABP levels were only sig-
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Table 2. Sensitivity, specificity, PPV and NPV values for patients with mesenteric ischemia and mass 
 AUC Cut-off Sensitivity Specificity PPV NPV
For mesenteric ischemia 0.755 144.9 71.4 94.6 41.7 98.4
For mass 0.695 14.7 60.0 83.8 30.0 94.8
nificantly higher in patients with acute mesenteric ischemia 
and intra-abdominal mass when compared with the control 
group. However, there were no significant differences be-
tween I-FABP values among subgroups (p>0.05).
Conclusions
Although average I-FABP levels of patients presenting to the 
emergency department with abdominal pain at the time of 
admission were higher than those of the healthy individuals, 
this difference was not statistically significant. Serum I-FABP 
levels of patients presenting with abdominal pain and diag-
nosed with mesenteric ischemia and intra-abdominal mass 
were significantly higher when compared to those of the 
healthy volunteers. Therefore, I-FABP levels may be used to 
diagnose such fatal pathologies. Further studies with wider 
series are needed in order to investigate the diagnostic val-
ue of I-FABP in patients with abdominal pain.
Limitation
The very low patient numbers in some of the subgroups 
made it impossible to obtain reliable statistical data. There-
fore, I-FABP should be investigated in wider study groups. 
Conflict of Interest
The authors declare that there is no potential conflicts of in-
terest.
References
1. Evennett NJ, Petrov MS, Mittal A, Windsor JA. Systematic 
review and pooled estimates for the diagnostic accuracy 
of serological markers for intestinal ischemia. World J Surg 
2009;33:1374-83. CrossRef
2. Acosta S, Nilsson TK, Björck M. D-dimer testing in patients 
with suspected acute thromboembolic occlusion of the su-
perior mesenteric artery. Br J Surg 2004;91:991-4. CrossRef
3. Acosta S, Nilsson TK, Björck M. Preliminary study of D-dimer 
as a possible marker of acute bowel ischaemia. Br J Surg 
2001;88:385-8. CrossRef
4. Solberg A, Holmdahl L, Falk P, Palmgren I, Ivarsson ML. A local 
imbalance between MMP and TIMP may have an implication 
on the severity and course of appendicitis. Int J Colorectal Dis 
2008;23:611-8. CrossRef
5. Gunduz A, Turkmen S, Turedi S, Mentese A, Yulug E, Ulusoy 
H, et al. Time-dependent variations in ischemia-modified 
albumin levels in mesenteric ischemia. Acad Emerg Med 
2009;16:539-43. CrossRef
6. Delaney CP, O’Neill S, Manning F, Fitzpatrick JM, Gorey TF. 
Plasma concentrations of glutathione S-transferase isoen-
zyme are raised in patients with intestinal ischaemia. Br J 
Surg 1999;86:1349-53. CrossRef
7. Bealer JF, Colgin M. S100A8/A9: a potential new diagnostic 
aid for acute appendicitis. Acad Emerg Med 2010;17:333-6. 
8. Acosta S, Nilsson T. Current status on plasma biomark-
ers for acute mesenteric ischemia. J Thromb Thrombolysis 
2012;33:355-61. CrossRef
9. Niewold TA, Meinen M, van der Meulen J. Plasma intestinal 
fatty acid binding protein (I-FABP) concentrations increase fol-
lowing intestinal ischemia in pigs. Res Vet Sci 2004;77:89-91.
10. Glatz JF, van der Vusse GJ. Cellular fatty acid-binding proteins: 
their function and physiological significance. Prog Lipid Res 
1996;35:243-82. CrossRef
11. Vermeulen Windsant IC, Hellenthal FA, Derikx JP, Prins MH, 
Buurman WA, et al. Circulating intestinal fatty acid-binding 
protein as an early marker of intestinal necrosis after aortic 
surgery: a prospective observational cohort study. Ann Surg 
2012;255:796-803. CrossRef
12. Relja B, Szermutzky M, Henrich D, Maier M, de Haan JJ, Lub-
bers T, et al. Intestinal-FABP and liver-FABP: Novel markers for 
severe abdominal injury. Acad Emerg Med 2010;17:729-35. 
13. Parker LJ, Vukov LF, Wollan PC. Emergency department eval-
uation of geriatric patients with acute cholecystitis. Acad 
Emerg Med 1997;4:51-5. CrossRef
14. Grundmann RT, Petersen M, Lippert H, Meyer F. The acute 
(surgical) abdomen - epidemiology, diagnosis and general 
principles of management. [Article in German] Z Gastroen-
terol 2010;48:696-706. [Abstract] CrossRef
15. Silen W. Abdominal pain. Harrison’s principles of internal 
medicine. 15th ed. Vol. I. 1998.
16. Akyildiz HY, Sözüer E, Akcan A, Küçük C, Artis T, Biri I, et al. 
The value of D-dimer test in the diagnosis of patients with 
nontraumatic acute abdomen. Ulus Travma Acil Cerrahi Derg 
2010;16:22-6.
17. Ockner RK, Manning JA. Fatty acid-binding protein in small 
intestine. Identification, isolation, and evidence for its role in 
cellular fatty acid transport. J Clin Invest 1974;54:326-38. CrossRef
18. Lores ME, Cañizares O, Rosselló PJ. The significance of eleva-
tion of serum phosphate levels in experimental intestinal 
ischemia. Surg Gynecol Obstet 1981;152:593-6.
19. Chen Y, Milles AM, Grisham BM. Pathophysiology and reactive 
oxygen metabolites. Oxidative stress and antioxidant defens-
es in biology. 1st ed. New York: Chapman and Hall Co; 1995. 
p. 62-95. CrossRef
20. Kanda T, Fujii H, Tani T, Murakami H, Suda T, Sakai Y, et al. 
Intestinal fatty acid-binding protein is a useful diagnostic 
marker for mesenteric infarction in humans. Gastroenterol-
ogy 1996;110:339-43. CrossRef
21. Kanda T, Nakatomi Y, Ishikawa H, Hitomi M, Matsubara Y, Ono 
T, et al. Intestinal fatty acid-binding protein as a sensitive 
marker of intestinal ischemia. Dig Dis Sci 1992;37:1362-7. CrossRef
22. Kanda T, Fujii H, Fujita M, Sakai Y, Ono T, Hatakeyama K. Intes-
tinal fatty acid binding protein is available for diagnosis of in-
testinal ischaemia: immunochemical analysis of two patients 
with ischaemic intestinal diseases. Gut 1995;36:788-91. CrossRef
23. Tölle A, Jung M, Lein M, Johannsen M, Miller K, Moch H, et 
al. Brain-type and liver-type fatty acid-binding proteins: new 
tumor markers for renal cancer? BMC Cancer 2009;9:248. CrossRef
103Uzun O et al. Intestinal Fatty Acid Binding Protein and Diagnosis of Abdominal Pathology
